Human nonmercaptalbumin-2: A novel prognostic marker in chronic liver failure

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 1, 2014, Pages 74-78

  Stauber, Rudolf E ^a   Spindelboeck, Walter ^a   Haas, Josef ^b   Putz Bankuti, Csilla ^a   Stadlbauer, Vanessa ^a   Lackner, Carolin ^c   Oettl, Karl ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Department of Gynecology and Obstetrics ^*  (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acute on chronic liver failure; Cirrhosis; Mercaptalbumin; Nonmercaptalbumin; Oxidative stress

Indexed keywords

ALBUMIN; CYSTEINE; CYSTEINE 34; HUMAN NONMERCAPTALBUMIN 2; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC LIVER FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUID THERAPY; HEPATORENAL SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MALE; MIDDLE AGED; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ACUTE-ON-CHRONIC LIVER FAILURE; CIRRHOSIS; MERCAPTALBUMIN; NONMERCAPTALBUMIN; OXIDATIVE STRESS;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDATION-REDUCTION; PROGNOSIS; ROC CURVE; SERUM ALBUMIN; YOUNG ADULT;

EID: 84893817191     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12024     Document Type: Article

References (21)

1. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988;8:385-401.
2. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16(Suppl 5):6-11.
3. Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984;24:96-103.
4. Hughes WL, Dintzis HM. Crystallization of the mercury dimers of human and bovine mercaptalbumin. J Biol Chem 1964;239:845-849.
5. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22(Suppl 2):5-13.
6. Sogami M, Era S, Nagaoka S etal. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr 1985;332:19-27.
7. Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S. Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004;20:351-357.
8. Oettl K, Stadlbauer V, Petter F etal. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008;1782:469-473.
9. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007;151:580-590.
10. Klammt S, Mitzner S, Stange J etal. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol 2007;19:257-263.
11. Jalan R, Schnurr K, Mookerjee RP etal. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009;50:555-564.
12. Arroyo V. Review article: albumin in the treatment of liver diseases-new features of a classical treatment. Aliment Pharmacol Ther 2002;16(Suppl 5):1-5.
13. Sort P, Navasa M, Arroyo V etal. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
14. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002;20:252-261.
15. Kawai K, Yoh M, Hayashi T etal. Effect of diabetic retinopathy on redox state of aqueous humor and serum albumin in patients with senile cataract. Tokai J Exp Clin Med 2001;26:93-99.
16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
17. Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol 2010;474:181-195.
18. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M. Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial. J Hepatol 2010;52:S459-460.
19. Kribben A, Gerken G, Haag S etal. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012;142:782-789. e3.
20. Klammt S, Mitzner SR, Stange J etal. Improvement of impaired albumin binding capacity in acute-on-chronic liver failure by albumin dialysis. Liver Transpl 2008;14:1333-1339.
21. Oettl K, Stadlbauer V, Krisper P, Stauber RE. Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 2009;13:431-436.